Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO906 in Advanced Renal Cancer
NCT00035243Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2002
- Primary completion
- Aug 2003
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of patupilone in renal cell carcinoma (RCC), sponsored by Novartis. Started Apr 2002; status: completed.
02
Drugs
patupilone
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00035243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035243.